ClinicalTrials.gg
RecruitingNCT07079553Updated Jul 23, 2025

Combined Effects of Transcutaneous Electrical Diaphragmatic Stimulation With ACBT'S in Copd

An interventional study of Transcutaneous Electrical Diaphragmatic Stimulation (TEDS) and Active Cycle of Breathing Techniques (ACBT) in COPD, sponsored by Riphah International University. Recruiting at 1 site in Pakistan. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Pulmonary Disease, Chronic Obstructive by Riphah International University — 18 open to participants now, 18 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Riphah International University.

Planned enrollment
19th of 55
50 · median 46
Started
2025
with 8 others
No phase
55 of 58
18 open now
Primary completion
2025-10
later than 9 of 17 live
Registered
49th of 58
by date

Among the 58 studies in Pulmonary Disease, Chronic Obstructive by Riphah International University, this one is the 19th largest by planned enrollment of the 55 interventional ones that give a count, is one of 9 that started in 2025, is one of 55 with no phase, reaches primary completion later than 9 of the 17 other live ones, and was the 49th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

18 of the 58 studies in Pulmonary Disease, Chronic Obstructive by Riphah International University are open now, in 1 country. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Pulmonary Disease, Chronic Obstructive by Riphah International University, or all of them as a file.
02

Study summary

The combined effects of transcutaneous electrical diaphragmatic stimulation (TEDS) and active cycle of breathing techniques (ACBTs) in patients with chronic obstructive pulmonary disease (COPD) conducted as a randomized controlled trial at Gulab Devi Hospital, the study involved 50 participants aged 40 to 60 with mild to moderate COPD. Participants were divided into two groups, one receiving both TEDS and ACBT, and the other receiving only ACBT. Over 12 weeks, improvements in lung function, oxygen saturation, exercise capacity, and quality of life were measured using spirometry, pulse oximetry, the 6-minute walk test, and the St. George's Respiratory Questionnaire. Both groups showed significant improvement, but the group receiving ACBT alone showed a slightly higher mean rank in some outcomes. The study concludes that while both interventions are beneficial, ACBT alone may offer more consistent improvements. It recommends including respiratory muscle assessments and combining interventions with education and exercise in future research.

Read the detailed description

This study investigates the effectiveness of combining transcutaneous electrical diaphragmatic stimulation (TEDS) with active cycle of breathing techniques (ACBTs) in the management of chronic obstructive pulmonary disease (COPD). COPD is a progressive respiratory condition characterized by airflow limitation, respiratory muscle weakness, and reduced quality of life. Non-pharmacological interventions like pulmonary rehabilitation, including TEDS and ACBT, have shown individual benefits in improving lung function and exercise tolerance in COPD patients. However, the combined effect of these interventions has not been extensively studied.

The research was designed as a randomized controlled trial conducted at Gulab Devi Hospital, Lahore. A total of 50 patients diagnosed with mild to moderate COPD, aged between 40 and 60 years, were recruited based on defined inclusion and exclusion criteria. Participants were randomly assigned to two groups: Group A received a combination of TEDS and ACBT, while Group B received ACBT alone. The intervention lasted for 12 weeks. TEDS was applied using specific settings-50Hz frequency, 300ms width, 6 seconds of stimulation followed by 5 seconds of rest. ACBT was administered through structured sessions involving breathing control, thoracic expansion, and forced expiratory techniques.

Outcome measures included forced expiratory volume in one second (FEV₁), forced vital capacity (FVC), FEV₁/FVC ratio, oxygen saturation (both at rest and post-exercise), six-minute walk test (6MWT) distance, and the St. George's Respiratory Questionnaire (SGRQ) for quality of life assessment. Data analysis was performed using SPSS version 25, and non-parametric tests were applied due to non-normal data distribution.

03

Conditions studied

  • COPD

Keywords

  • COPD, TEDS, ACBT, transcutaneous electrical diaphragmatic stimulation, Active Cycle of Breathing Techniques.
04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (Mild to Moderate)
  • Age: 40-60 years of both genders
  • Productive cough for more than 2 months
  • Oxygen saturation without Oxygen supply > 88%

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled hypertension
  • Cardiac diseases
  • Active smokers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    TEDS + ACBT

    Participants receive transcutaneous electrical diaphragmatic stimulation (TEDS) along with active cycle of breathing techniques (ACBTs) daily for 12 weeks.

    Device: Transcutaneous Electrical Diaphragmatic Stimulation (TEDS) · Behavioral: Active Cycle of Breathing Techniques (ACBT)

  • Active comparator
    ACBT only

    Participants receive only active cycle of breathing techniques (ACBTs) daily for 12 weeks.

    Behavioral: Active Cycle of Breathing Techniques (ACBT)

Interventions

  • DeviceTranscutaneous Electrical Diaphragmatic Stimulation (TEDS)

    TEDS was applied using surface electrodes placed over the diaphragm region. The stimulation protocol was set at 50 Hz frequency, 300 μs pulse width, with 6 seconds of stimulation followed by 5 seconds of rest, daily for 12 weeks. It was combined with ACBT sessions.

    Also known as: Active Cycle of Breathing Techniques (ACBT)

  • BehavioralActive Cycle of Breathing Techniques (ACBT)

    ACBT sessions included breathing control, thoracic expansion exercises, and forced expiration techniques (huffing). Sessions were performed daily for 12 weeks to aid in secretion clearance and improve lung function.

06

What researchers measure

Primary outcomes

  1. Forced Expiratory Volume in 1 second (FEV1) using Spirometry

    FEV1 measures the volume of air that can be forcibly exhaled in one second. It is a key indicator of airway obstruction and lung function in COPD patients.

    Time frame: 12 weeks

  2. Forced Vital Capacity (FVC) using Spirometry

    FVC measures the total amount of air that can be forcibly exhaled after taking the deepest breath possible.

    Time frame: 12 weeks

  3. FEV1/FVC Ratio using Spirometry

    using Spirometry

    Time frame: 12 weeks

  4. St. George's Respiratory Questionnaire (SGRQ)

    Assesses health-related quality of life specific to respiratory diseases

    Time frame: baseline and at 12 weeks post intervention

  5. 6-Minute Walk Test (6MWT)

    Assesses functional exercise capacity.

    Time frame: Baseline and at 12 weeks post-intervention

Secondary outcomes

  1. Oxygen Saturation after 6-Minute Walk Test (6MWT) via Pulse Oximetry

    Evaluates oxygen desaturation during physical exertion, reflecting exercise tolerance and pulmonary reserve.

    Time frame: Baseline and at 12 weeks post-intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Oct 2025, 5 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 5 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 23, 2025
StartActual
May 28, 2025
Primary completionEst.
Oct 28, 2025
CompletionEst.
Nov 10, 2025
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07079553
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
May 28, 2025
Primary completion
Oct 28, 2025 (estimated)
Completion
Nov 10, 2025 (estimated)
Last update
Jul 23, 2025

Study contacts

imran amjad, phd
Contact
imran.amjad@riphah.edu.pk
03324390125
Arjumand Bano, MS-CPPT
principal investigator · Riphah International University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion